Post by Wallace907 on Feb 9, 2016 18:00:17 GMT
kind of an interesting company Im starting to follow.
Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) announced today that after a seven-day bench trial, New Jersey District Court Judge Renee Marie Bumb has ruled in its favor, with regard to Oxtellar XR’s abbreviated new drug application (ANDA) litigation, which claimed that Actavis and its subsidiaries had infringed its patents. Actavis merged with Allergan (NYSE:AGN) in March 2015.
According to analyst David Steinberg, the ruling suggests that the company holds a stronger-than-expected patent estate.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing products for the treatment of central nervous system diseases. The Company launched its two products in neurology for the treatment of epilepsy, which include Oxtellar XR and Trokendi XR. It is also engaged in developing multiple product candidates in psychiatry to address the medical needs and market opportunities in impulsive aggression across several areas (such as attention deficit hyperactivity disorder (ADHD), autism and bipolar disorder), and ADHD. The Company markets its products in the United States through its own specialty sales force and has collaborations with other pharmaceutical companies to license its products outside the United States. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which are indicated for epilepsy in the United States. Its product candidates include Oxtellar XR, Trokendi XR, SPN-810, SPN-812 and SPN-809.
Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) announced today that after a seven-day bench trial, New Jersey District Court Judge Renee Marie Bumb has ruled in its favor, with regard to Oxtellar XR’s abbreviated new drug application (ANDA) litigation, which claimed that Actavis and its subsidiaries had infringed its patents. Actavis merged with Allergan (NYSE:AGN) in March 2015.
According to analyst David Steinberg, the ruling suggests that the company holds a stronger-than-expected patent estate.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing products for the treatment of central nervous system diseases. The Company launched its two products in neurology for the treatment of epilepsy, which include Oxtellar XR and Trokendi XR. It is also engaged in developing multiple product candidates in psychiatry to address the medical needs and market opportunities in impulsive aggression across several areas (such as attention deficit hyperactivity disorder (ADHD), autism and bipolar disorder), and ADHD. The Company markets its products in the United States through its own specialty sales force and has collaborations with other pharmaceutical companies to license its products outside the United States. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which are indicated for epilepsy in the United States. Its product candidates include Oxtellar XR, Trokendi XR, SPN-810, SPN-812 and SPN-809.
